Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania Show more

Location: 125 Strafford Avenue, Wayne, PA, 19087, United States | Website: https://palvellatx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

651.1M

52 Wk Range

$11.17 - $63.12

Previous Close

$58.87

Open

$60.03

Volume

119,553

Day Range

$57.38 - $60.03

Enterprise Value

580.6M

Cash

70.43M

Avg Qtr Burn

-5.084M

Insider Ownership

22.86%

Institutional Own.

54.89%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
QTORIN Rapamycin Details Microcystic Lymphatic Malformations	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
QTORIN Rapamycin Details Cutaneous Venous Malformations	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
QTORIN Rapamycin Details Angiokeratomas	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.